Evidence map›Paper›PMID 31285528›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.

Ken-Ichi Yoshida, Yoshiko Nakano, Mai Honda-Kitahara, Susumu Wakai, Toru Motoi, Koichi Ogura, Naoki Sano, Tatsuhiro Shibata, Tomotake Okuma, Shintaro Iwata and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Clinical pathological characteristics correlation ofTranslational cancer research · 2025
    Article
  5. Review
  6. Frontiers in medicine · 2025
    Article
  7. Article
  8. Article
  9. Rare features of giant cell tumors of the bone: A case report.Experimental and therapeutic medicine · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy.Virchows Archiv : an international journal of pathology · 2023
    Article
  15. Article
  16. Article
  17. Diagnostic value ofJournal of bone oncology · 2023
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Ken-Ichi YoshidaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1549-1514
Yoshiko NakanoDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5394-8194
Mai Honda-KitaharaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Susumu WakaiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Toru MotoiDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Koichi OguraDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Naoki SanoDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Tomotake OkumaDepartment of Orthopedic Surgery and Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shintaro IwataDepartment of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3851-2349
Akihiko YoshidaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. akyoshid@ncc.go.jp.ORCID http://orcid.org/0000-0002-3373-0099
Tokyo Metropolitan Komagome Hospital · JPTokyo National Hospital · JPNational Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giant cell tumor of bone typically involves the epiphysis of the long bones of skeletally mature patients. It is genetically characterized by highly recurrent and specific mutations of the H3F3A gene, which encodes histone H3.3. The most common mutation H3F3A G34W can readily be detected by a recently developed mutation-specific antibody. Giant cell tumor of bone rarely transforms to a sarcoma (malignant giant cell tumor of bone), which has not been genetically characterized in detail. We studied seven clinicopathologically defined malignant giant cell tumors, as well as two H3F3A-mutant bone sarcomas without giant cell tumor histology using a combination of clinicopathological, immunohistochemical, and molecular methods (Sanger sequencing + pyrosequencing or next generation sequencing). The cases included five men and four women, with a median age at initial diagnosis of 27 years. The two H3F3A G34W-positive sarcomas without giant cell tumor histology involved the subarticular epiphyseal sites, suggesting relatedness with giant cell tumor of bone. In two of the seven clinicopathologically defined malignant giant cell tumor cases, the sarcoma tissue showed the H3F3A G34W mutation. However, in the remaining five cases, in contrast to their associated H3F3A G34W-mutant giant cell tumor, the sarcoma lacked the H3F3A G34W mutation, either entirely or sub-clonally in the samples tested. This discordant mutation status was confirmed in all instances by immunohistochemistry and sequencing. A FISH analysis suggested that the absence of the H3F3A G34W mutation may be related to deletion of the H3F3A gene. Therefore, we have demonstrated that H3F3A G34W mutation, a critical driver in giant cell tumor, is absent in a subset of malignant giant cell tumor of bone. This novel recurrent phenomenon has potential biological and diagnostic implications, and further study is required to better characterize this progression pathway and understand its mechanism.

Indexed as

AdultBone NeoplasmsFemaleGiant Cell Tumor of BoneHistonesHumansMaleMutationH3-3A protein, humanHistones

Identifiers

PMID31285528
OpenAlexW2957975594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.